NCI-2023-09677

A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered asmonotherapy and in combination with cetrelimab and radiotherapy for advanced nonsmallcell lung cancer

This is a phase 1 study trying out a drug called JNJ-86974680 alone and with cetrelimab, an immunotherapy medication, and radiotherapy for advanced non small cell lung cancer.

phase 1 study: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

immunotherapy medication: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

non small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06116786

Clinical Trial Site: Columbia

To see all available clinical trials click here.